Peptide–oligonucleotide nanohybrids deliver miRNA to injured bone in rats
Academic source · Nature Communications
Source published: · Event / reporting date: 2026-11-05
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What the paper reports
A Nature Communications study reports a peptide–oligonucleotide nanohybrid for bone-targeted miR-26a-5p delivery. The original abstract describes reduced GSK-3β expression and stabilization of HIF-1α, supporting coupled bone formation and angiogenesis. Systemic administration limited skeletal and vascular injury in a rat glucocorticoid-induced bone-loss model. This is preclinical miRNA delivery, not oral cyclic peptide therapy or human efficacy evidence.
Why this paper is included
Analysis: Pathology-responsive extrahepatic delivery may broaden oligonucleotide applications, with biodistribution, repeat-dose safety, and scalable manufacture still requiring further evaluation.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Edited by the Biotech Assistant content team and reviewed by an authorized publisher. Editorial standards and corrections
Oligonucleotide Therapeutics & Delivery Formulation Development & Manufacturing